EMUC24: A new collaboration with the Kidney Cancer Association
This year, the 16th European Multidisciplinary Congress on Urological Cancers (EMUC24) will feature two plenary sessions designed by the Kidney Cancer Association (KCA). This new collaboration enables the dissemination of their kidney cancer updates within a multidisciplinary environment. The KCA’s involvement ensures that the EMUC24 congress addresses the most pressing issues in kidney cancer treatment, providing delegates with a comprehensive understanding of current practices and future directions.
Dr. Salvatore La Rosa (US), Chief Scientific Officer of the KCA is enthusiastic about their contribution to the EMUC24 programme: “As a non-profit advocacy organisation, we are thrilled to collaborate with EMUC this year to deliver cutting-edge research summaries and valuable kidney cancer education to attendees. Our aim is to empower clinicians with the knowledge and tools they need to provide the highest quality care for their patients.”
“In today’s digital age, patients and their families have access to vast amounts of information online about their diagnoses. However, it's crucial that they receive accessible, evidence-based, and up-to-date information about kidney cancer to make informed decisions and advocate for their options. We hope to reach more health professionals with information that can be passed on to their patients, ultimately helping them to navigate their cancer journey with confidence.”
“For KCA, whose mission is to find a cure for kidney cancer, this collaboration is a unique opportunity to bring together experts from various specialties to address the latest topics and challenges in renal cancer. This is particularly significant with urologists, who are often not as involved in kidney cancer patient care as they should. By leveraging the EMUC platform, we also aim to draw more attention from other specialists to kidney cancer and attract them to the field by presenting them with the unique challenges our patients face at every step of their journey.”
What’s on the agenda?
The first KCA plenary session will take place on Friday 8 November from 16:15 till 17:30 and will feature presentations on several key practice-changing studies, including trial results from FASTRACK, KEYNOTE 564 OS, and SUNNiFORCAST. There will also be a debate on evidence for local tumour control in metastatic RCC with a review of current retrospective data and ongoing phase II and III trials in this setting. For cytoreductive nephrectomy, urologist Dr. Géraldine Pignot (FR) will present on PROBE and NORDICSUN, and for radiation oncologist, Dr. Anna Bruynzeel (NL) will present on stereotactic ablative body radiotherapy (SABR).
Experience a WoodFire® session
The second KCA Plenary Session will take place on Saturday 9 November from 11:40 till 12:45 and will introduce a unique format to the EMUC24 programme called a WoodFire® session.
Dr. La Rosa explains: “This is essentially a live tumour board. It got its name due to the quick-fire, high-pressure nature of how our late Board of Directors Chair, Dr. Christopher G. Wood, a renowned surgeon at MD Anderson Cancer Center in Houston, Texas, grilled his peers about how they might treat someone with kidney cancer – all in good fun! It is fascinating to hear how differently a surgeon might approach a single case versus a medical oncologist versus a urologist, and so on. WoodFire® is both a glimpse at how much we must learn from each other and a testament to how much everyone cares about achieving a good outcome for the patient.”
---
The 16th European Multidisciplinary Congress on Urological Cancers (EMUC24) is set to take place in Lisbon, Portugal from 7-10 November 2024. Each year the congress brings together leading experts across various genitourinary cancer disciplines to share their insights on best practices, key clinical trial developments, and the latest scientific advancements. You can view the full EMUC24 scientific programme and take advantage of registration savings if you sign up before 24 October, 2024 (23:59 CEST).
